Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate by Wells, G et al.
Validation of the 28-joint Disease Activity Score
(DAS28) and European League Against Rheumatism
response criteria based on C-reactive protein against
disease progression in patients with rheumatoid
arthritis, and comparison with the DAS28 based on
erythrocyte sedimentation rate
G Wells,
1 J-C Becker,
2 J Teng,
2 M Dougados,
3 M Schiff,
4 J Smolen,
5 D Aletaha,
6
P L C M van Riel
7
1Department of Epidemiology
and Community Medicine,
University of Ottawa, Ottawa,
Canada;
2Bristol-Myers Squibb,
Princeton, New Jersey, USA;
3Paris-Descartes University,
Medicine Faculty and UPRES-EA
4058, AP-HP, Cochin Hospital,
Paris, France;
4University of
Colorado, Denver, Colorado,
USA;
5Second Department of
Medicine, Hietzing Hospital,
Vienna, Austria;
6Department of
Rheumatology, Medical
University of Vienna, Vienna,
Austria;
7University Medical
Centre, Nijmegen, The
Netherlands
Correspondence to:
Professor G Wells, Department
of Epidemiology and Community
Medicine, University of Ottawa,
451 Smyth Road, Ottawa,
Ontario, K1H 8M5, Canada;
gawells@ottawaheart.ca
Accepted 9 April 2008
Published Online First
19 May 2008
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
ard.bmj.com/info/unlocked.dtl
ABSTRACT
Objective: To validate and compare the definition of the
Disease Activity Score 28 based on C-reactive protein
(DAS28 (CRP)) to the definition based on erythrocyte
sedimentation rate (ESR).
Methods: Data were analysed from two randomised,
double-blind, placebo-controlled trials of abatacept of 6-
month and 12-month duration in patients with rheumatoid
arthritis. European League Against Rheumatism (EULAR)
response criteria and the proportion of patients in
remission (DAS28 ,2.6) based on the two DAS28
definitions were examined. Trends in radiographic
progression (erosion score, joint space narrowing score
and total score) and physical function (Health Assessment
Questionnaire Disability Index (HAQ-DI)) across the EULAR
responder states (none, moderate and good) were
analysed.
Results: There was general agreement in determining
the EULAR responder state using both DAS28 definitions
(k=0.80, 95% CI 0.76 to 0.83). Overall, there was
82.4% agreement on the EULAR response criteria; when
disagreements occurred, the DAS28 (CRP) yielded a
better EULAR response more often then DAS28 (ESR)
(12.6% vs 4.9%, respectively). There was also agreement
in determining remission: k=0.69 (95% CI 0.60 to 0.78).
Radiographic progression decreased in patients treated
with abatacept across EULAR states (from none to
moderate to good) based on both definitions. For patients
treated with placebo, the trend was not as pronounced,
with radiographic scores higher for moderate vs non-
responders. For physical function, similar trends were
observed across the EULAR states for both DAS28
definitions.
Conclusions: The DAS28 (CRP) has been validated
against radiographic progression and physical function.
While the DAS28 (CRP) yielded a better EULAR response
more often than the DAS28 (ESR), the validation profile
was similar to the DAS28 (ESR), indicating that both
measures are useful for assessing disease activity in
patients with rheumatoid arthritis.
Agreement on response criteria in rheumatoid
arthritis (RA) has allowed better standardisation
and interpretation of clinical trial reports. In
particular, American College of Rheumatology
(ACR) criteria
1 and the Disease Activity Score
(DAS)
2 are widely used. The DAS index combines
information relating to the number of swollen and
tender joints, in addition to a measure of general
health, and the acute phase response. The DAS28
3
is based on a count of 28 swollen and tender joints,
with a score ranging from 0 to 9.4,
4 and can be used
to objectively evaluate a patient’s response to
treatment. An absolute level of disease activity
can be selected as a clinically meaningful goal for
therapeutic intervention; with a value of (3.2
defined as the threshold for a low disease activity
state and ,2.6 as the threshold for remission.
5
Alternatively, the European League Against
Rheumatism (EULAR) response criteria combine
the DAS28 score at the time of evaluation with the
change in DAS28 score between two time points,
and enable the user to define improvement or
response to treatment.
5 The thresholds for low
disease activity and remission and the EULAR
response criteria provide a standardised guide on
how to interpret the DAS28 scores.
467The DAS28
based on erythrocyte sedimentation rate (DAS28
(ESR)) has been extensively validated for its use in
clinical trials in combination with the EULAR
response criteria.
3 5 8–11
More recently, an alternative formulation of the
DAS28 based on C-reactive protein (DAS28 (CRP))
has been proposed and developed.
12 At the present
time, the DAS28 (CRP) is not as well established as
the DAS28 (ESR), and its validity is currently only
inferred by comparison with the DAS28 (ESR). A
comparison of the two DAS28 definitions and a
formal validation of the DAS28 (CRP) is necessary
so that the clinician or patient will have the same
confidence using and interpreting the DAS28
(CRP) that they have come to expect when using
the DAS28 (ESR). To properly evaluate the validity
of the DAS28 (CRP), a well controlled study with
assessment of radiographic progression and physi-
cal function is needed in a setting in which a
change in patient clinical status has occurred. The
ATTAIN (Abatacept Trial in Treatment of Anti-
tumor necrosis factor (TNF) INadequate respon-
ders) and AIM (Abatacept in Inadequate respon-
ders to Methotrexate (MTX)) trials of the selective
costimulation modulator abatacept (which mod-
ulates the CD80/CD86:CD28 signal required for
Extended report
954 Ann Rheum Dis 2009;68:954–960. doi:10.1136/ard.2007.084459full T cell activation) provide such an opportunity.
13 14 Both
studies were well controlled, and the measures required for
validation of the DAS28 (CRP) were recorded. Significant
improvements in clinical measures of disease activity, physical
function and health-related quality of life were observed with
active treatment vs placebo in both trials. In addition,
radiographic assessments were taken during the AIM trial,
and patients treated with abatacept demonstrated significant
reductions in structural progression compared with patients
treated with placebo.
14 Using data from these two trials, the
objective of this investigation was to: (1) compare the DAS28
(CRP) with the DAS28 (ESR) by crossclassifying EULAR
response states and the proportion of patients achieving
DAS28-defined remission; and (2) to validate the DAS28
(CRP) against assessments of radiographic progression and
physical function.
METHODS
Datasets
Data from two phase III, multicentre, randomised, double-
blind, placebo-controlled trials of abatacept in patients with
active RA were used in this analysis. In the 6-month ATTAIN
trial, patients with an inadequate response to anti-TNF therapy
received abatacept or placebo, plus >1 disease-modifying
antirheumatic drug.
13 In the 12-month AIM trial, patients with
an inadequate response to MTX received abatacept or placebo,
plus MTX.
14
Data are presented for all patients in the ATTAIN and AIM
trials for whom ESR and CRP measurements were available.
Measures of disease activity
Efficacy assessments were taken on study visit days, prior to
infusion. The DAS28 considers 28 tender and swollen joint
counts, general health (GH; patient assessment of disease
activity using a 100 mm visual analogue scale (VAS) with
0=best, 100=worst), plus levels of an acute phase reactant
(either ESR (mm/h) or CRP (mg/litre)). DAS28 values were
calculated as follows: DAS28 (CRP)=0.56*!(TJC28)
+0.28*!(SJC28)+0.014*GH+0.36*ln(CRP+1)+0.96; DAS28
(ESR)=0.56*!(TJC28)+0.28*!(SJC28)+0.014*GH+0.70*ln(ESR),
where TJC=tender joint count and SJC=swollen joint count.
EULAR response states were classified as follows: good
responders were patients with an improvement of .1.2 and a
present score of (3.2; moderate responders were patients with
an improvement of .0.6 to (1.2 and a present score of (5.1,
or an improvement of .1.2 and a present score of .3.2; non-
responders were any patients with an improvement of (0.6, or
patients with an improvement of .0.6 to (1.2 and a present
score of .5.1.
4 DAS28-defined remission was classified as a score
of ,2.6.
Physical function was measured at baseline and every
3 months using the Health Assessment Questionnaire
Disability Index (HAQ-DI).
15 In the AIM trial, joints in the
hands, wrists and feet were assessed radiographically at baseline
and 1 year for changes in erosion score (ES), joint space
narrowing (JSN) score and total score (TS) using the Genant-
modified Sharp scoring system.
16–19
Validation analyses for the disease activity score 28 (CRP)
Criterion validity
To assess the extent of agreement between the two DAS28
definitions, the EULAR response criteria based on each
definition were calculated by treatment group and for pooled
treatment groups, with crossclassification for each of the
datasets. The proportion of patients who achieved remission
according to the two DAS28 definitions was calculated for the
pooled treatment groups. K coefficients with quadratic weights
were calculated and Bland–Altman plots
20 were constructed.
Construct validity
To examine the extent to which the DAS28 (CRP) reflects
structural damage and physical function, trends in radiographic
progression and HAQ-DI scores across the EULAR responder
states based on the DAS28 (CRP) and the DAS28 (ESR) were
assessed, and trends based on the two DAS28 definitions were
compared.
Sensitivity to change
To examine the ability of the two DAS28 definitions to detect a
treatment effect, the following measures were assessed:
21
treatment difference, relative percentage improvement, stan-
dardised response mean (SRM) and relative efficiency in relation
to the tender joint count.
RESULTS
Of the 258 and 133 patients randomised and treated with
abatacept or placebo, respectively, in the ATTAIN trial, 171
patients treated with abatacept and 75 patients treated with
placebo had ESR and CRP measurements available for analysis.
Of the 433 and 219 patients randomised and treated with
abatacept or placebo, respectively, in the AIM trial, 351 patients
treated with abatacept and 155 patients treated with placebo
had ESR and CRP measurements available for analysis. Baseline
demographics and clinical characteristics were generally similar
for the abatacept and placebo groups in each study (table 1).
Baseline demographics and clinical characteristics were compar-
able between this subset of patients, and the subset of patients
who did not have DAS28 (CRP) and DAS28 (ESR) available
(data not shown).
Table 2 shows the crossclassification of the EULAR response
criteria based on DAS28 (ESR) and DAS28 (CRP) at 6 months
for patients in both treatment groups for the ATTAIN and AIM
trials combined. There was general agreement in classifying
patients as none, moderate and good EULAR responders using
the two DAS28 definitions, with a k (95% CI) of 0.80 (0.76,
0.83) indicating good agreement. The main diagonal numbers in
table 2 indicate where the EULAR response criteria based on
DAS28 (ESR) and DAS28 (CRP) are in agreement. Overall there
was an 82.4% agreement between the EULAR response criteria
based on the two definitions (table 2). When disagreements
occurred, the DAS28 (CRP) yielded a better EULAR response
state more often than the DAS28 (ESR) (12.7% vs 4.9%,
respectively). In one instance, a patient was classified as being a
non-responder with DAS28 (CRP) but a good responder with
DAS28 (ESR). This patient had a CRP value of 22.4 mg/dl and
an ESR value of 4.0 mm/h, corresponding to a DAS28 (CRP)
score of 4.3 and a DAS28 (ESR) score of 2.4. The patient
subsequently discontinued from the ATTAIN trial due to
cholangiocarcinoma, which was the probable cause of the
elevated CRP levels.
Similar patterns were observed when the ATTAIN and AIM
trials were considered separately, and when treatment groups
were considered combined or separately (data not shown). A
total of 50/752 (6.6%) patients were classified as having
achieved remission according to both DAS28 definitions. A
total of 83 (11.0%) patients were classified as having achieved
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having achieved remission with the DAS28 (ESR). The k
coefficient (95% CI) was 0.69 (0.60 to 0.78), indicating good
agreement. A Bland–Altman plot (fig 1) shows a high degree of
agreement between the two DAS28 definitions with most
observations of the difference between DAS28 (ESR) and
DAS28 (CRP) lying between the mean ¡2SD (represented in
the figure by central and outer horizontal dashed lines,
respectively). A total of 3.3% of values fell outside 2SD above
the mean difference and 1.5% fell outside 2SD below the mean
difference, indicating that when disagreement of two defini-
tions occurred, there were more instances in which DAS28
(CRP) was lower than DAS28 (ESR) compared with instances in
which it was higher. The mean difference between DAS28
(CRP) and DAS28 (ESR) is 20.38, indicating a relatively small
tendency for the DAS28 (ESR) to classify patients as having a
higher score.
Radiographic progression was assessed in the AIM trial.
14
For both definitions, there were several instances in which
radiographic progression did not improve in a linear fashion
across the EULAR responder states. This was particularly
apparent in the placebo group, where ES, JSN score and TS
improved in a quadratic manner with a sharp improvement for
good vs moderate responders but a more modest improvement
for moderate vs non-responders, and in the case of the DAS28
(CRP) definition a slight deterioration was observed for
moderate vs non-responders (table 3). Similar patterns were
observed for ES in the abatacept group and in both groups
combined. The JSN score in the abatacept group using the
DAS28 (ESR) definition followed a more linear pattern across
the EULAR responder states, which in turn led to a linear
pattern for the JSN scores in both groups combined and for TS
in the abatacept and combined groups. For the DAS28 (CRP)
definition, the JSN scores and TS followed the quadratic
pattern.
Table 4 and fig 2 show data from the ATTAIN and AIM
trials, illustrating the mean improvements from baseline in
HAQ-DI at 6 months in patients who were EULAR good,
Table 1 Baseline demographics and clinical characteristics for all randomised and treated patients with C-
reactive protein (CRP) and erythrocyte sedimentation rate (ESR) measurements available
ATTAIN AIM
Abatacept +
DMARDs n=171
Placebo + DMARDs
n=75
Abatacept + MTX
n=351
Placebo + MTX
n=155
Age, years 52.5 (12.1) 52.5 (12.0) 50.8 (12.7) 49.5 (11.6)
Gender, % female 77.2 80.0 77.2 83.2
Race, % Caucasian 96.5 93.3 87.7 86.5
Disease duration, years 12.0 (8.1) 11.7 (9.0) 8.5 (7.1) 8.9 (7.0)
Tender joints 30.9 (13.4) 31.0 (13.6) 31.1 (12.8) 33.7 (13.9)
Swollen joints 22.6 (10.4) 22.1 (10.1) 21.3 (8.3) 22.3 (8.3)
Erosion score* N/A N/A 22.4 (18.3) 22.1 (19.7)
Joint space narrowing score* N/A N/A 23.3 (20.1) 23.7 (21.3)
Total score* N/A N/A 45.7 (37.4) 45.8 (39.8)
Pain assessment, 100 mm VAS 69.5 (20.5) 68.0 (19.0) 63.1 (21.1) 67.3 (18.9)
Physical function, HAQ-DI 1.8 (0.5) 1.7 (0.6) 1.7 (0.7) 1.7 (0.6)
Patient global assessment, 100 mm
VAS
68.2 (19.6) 66.7 (22.0) 63.2 (20.9) 63.8 (20.6)
Physician global assessment,
100 mm VAS
67.7 (17.7) 63.7 (18.2) 69.3 (15.3) 68.2 (15.9)
Levels of CRP, mg/dl 4.4 (3.6) 3.5 (3.3) 3.3 (3.2) 2.5 (2.1)
ESR, mm/h 49.9 (27.7) 43.7 (26.9) 44.1 (23.5) 43.0 (24.5)
DAS28 (CRP) 6.5 (0.9) 6.4 (0.8) 6.4 (0.8) 6.4 (0.8)
DAS28 (ESR) 6.9 (1.0) 6.8 (1.0) 6.8 (0.9) 6.9 (0.8)
Data are mean (SD) unless otherwise stated.
*Values represent baseline readings for all patients with radiographic data at day 365 (n=328 for abatacept; n=137 for placebo).
AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate
responders; DAS28, 28-joint Disease Activity Score; DMARD, disease-modifying antirheumatic drug; HAQ-DI, Health Assessment
Questionnaire Disability Index; MTX, methotrexate; N/A, not applicable; VAS, visual analogue scale.
Table 2 Crossclassification of patients by the European League Against Rheumatism (EULAR) response
criteria based on the 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP) and DAS28 erythrocyte
sedimentation rate (ESR) scales at 6 months (AIM (Abatacept in Inadequate responders to Methotrexate) and
ATTAIN (Abatacept Trial in Treatment of Anti-TNF INadequate responders) trials, both treatment groups
combined*)
DAS28 (CRP)
Good responder n (%)
Moderate responder n
(%) Non-responder n (%)
DAS28 (ESR) Good responder n (%) 108 (14.4){ 12 (1.6) 1 (0.1)
Moderate responder n
(%)
56 (7.4) 352 (46.8){ 24 (3.2)
Non-responder n (%) 0 (0) 39 (5.2) 160 (21.3){
*n=752, based on all randomised and treated patients with CRP and ESR measurements available; {indicates agreement between
EULAR response criteria based on DAS28 (ESR) and DAS28 (CRP).
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DAS28 (ESR) definition. For both definitions, function
improved in a linear fashion across the EULAR responder states,
and there was agreement on the changes in HAQ-DI scores
across the states. For the good and moderate states, there was
improvement from baseline in HAQ-DI, and this improvement
was more marked in good responders compared with moderate
responders. For EULAR non-responders, HAQ-DI scores showed
little improvement at 6 months. Similar results were observed
for patients in the AIM trial at 1 year. For the combined
(abatacept and placebo) group, the mean change from baseline
in HAQ-DI was 20.92 and 21.03 for good responders 20.62
and 20.64 for moderate responders and 20.27 and 20.27 for
non-responders, for DAS28 definitions based on CRP and ESR,
respectively.
Measures to assess the sensitivity of the two DAS28 definitions
demonstrate that both have a comparable ability to detect a
treatment effect. For the DAS28 (CRP) and DAS28 (ESR),
respectively, the treatment difference was 218.83 vs 213.22;
the percentage improvement was 214.42 vs 27.44; the SRM was
20.31 vs 20.31 and the relative efficiency was 1.93 vs 1.97.
DISCUSSION
Using CRP for calculation of the DAS28 is an attractive
alternative to ESR for a number of reasons. Firstly, CRP
measurements are routinely used in clinical practice, and are
often available in circumstances when ESR measurements are
not. CRP levels are more sensitive to short-term changes in
disease activity,
22 whereas ESR can be influenced by a number of
unrelated factors, such as age, gender or plasma proteins.
Laboratory tests used to calculate CRP are faster than those
used to measure ESR, and measurements can be standardised in
a central laboratory for multicentre clinical trials.
7 There is
currently less clinical experience using DAS28 (CRP), and a
formal validation study with respect to radiographic progression
and functional assessment is needed.
Using data from two trials of abatacept, we have compared
the DAS28 (CRP) with the DAS28 (ESR), and validated the
DAS28 (CRP) against assessments of radiographic progression
and physical function. Most patients were classified as having
the same EULAR state regardless of which DAS28 definition is
used. Despite this, several discrepancies were observed. Firstly,
some patients (154/752; 20.5%) were classified as having a lower
present DAS28 category when using the DAS28 (CRP) vs the
DAS28 (ESR). In 76 out of these 154 cases, this resulted in
patients being classified as being in a better EULAR state when
measured with DAS28 (CRP). Secondly, certain patients were
classified as having either large or moderate improvement,
depending on which DAS28 definition was used; this type
of discrepancy occurred at a similar frequency with both
Figure 1 Bland–Altman plot of 28-joint
Disease Activity Score (DAS28) C-
reactive protein (CRP) and DAS28
erythrocyte sedimentation rate (ESR)
values for patients in the ATTAIN
(Abatacept Trial in Treatment of Anti-TNF
INadequate responders) and AIM
(Abatacept in Inadequate responders to
Methotrexate) trials (both treatment
groups) at 6 months. Difference between
DAS28 (ESR) and DAS28 (CRP) scores vs
mean value of DAS28 (ESR) and DAS28
(CRP) score combined for patients in the
ATTAIN and AIM trials (both treatment
groups) at 6 months. The central line
represents the mean difference between
the two measures, and the upper and
lower bounds represent 2SD from the
mean.
Table 3 Radiographic progression across the European League Against Rheumatism (EULAR) states based on the 28-joint Disease Activity Score
(DAS28) C-reactive protein (CRP) and DAS28 erythrocyte sedimentation rate (ESR) values: mean change from baseline to 12 months (AIM (Abatacept
in Inadequate responders to Methotrexate) trial)
Radiographic assessment EULAR response
Abatacept group (n=328) Placebo group (n=137) Combined group (n=465)
CRP ESR CRP ESR CRP ESR
Erosion score Good 0.37 (1.13) 0.37 (1.17) 0.41 (1.15) 0.10 (0.23) 0.37 (1.13) 0.35 (1.14)
Moderate 0.72 (1.70) 0.63 (1.56) 1.48 (3.70) 1.36 (3.50) 0.98 (2.59) 0.85 (2.34)
None 0.68 (1.17) 0.65 (1.12) 1.16 (2.07) 1.26 (2.29) 0.97 (1.78) 1.03 (1.94)
Joint space narrowing score Good 0.44 (1.11) 0.41 (1.17) 0.86 (2.27) 0.43 (0.84) 0.47 (1.23) 0.41 (1.16)
Moderate 0.69 (1.80) 0.59 (1.43) 1.47 (2.86) 1.34 (2.76) 0.96 (2.25) 0.82 (1.96)
None 0.56 (1.26) 1.00 (2.63) 1.13 (1.96) 1.35 (2.23) 0.91 (1.73) 1.22 (2.37)
Total score Good 0.81 (1.93) 0.77 (2.09) 1.27 (3.31) 0.53 (0.84) 0.84 (2.06) 0.76 (2.04)
Moderate 1.41 (3.03) 1.22 (2.60) 2.94 (6.30) 2.70 (6.03) 1.94 (4.49) 1.67 (4.01)
None 1.25 (2.26) 1.65 (3.39) 2.29 (3.74) 2.61 (4.13) 1.88 (3.27) 2.25 (3.86)
Data are mean (SD).
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favourable results with one definition vs the other. Although
the current analysis detected discrepancies in 17.6% of patients,
these were moderate in magnitude; overall, there is general
agreement between the two measures. The 2 DAS28 definitions
also demonstrated agreement in classifying DAS28-defined
remission, with the majority of discrepancies (33 cases)
resulting in patients being classified as in remission with
DAS28 (CRP) but not DAS28 (ESR). Considering the DAS28
(ESR) definition as the external comparison, there is support for
the criterion validity of the DAS28 (CRP).
When a discrepancy occurs, the tendency is for the DAS28
(CRP) definition to yield a better response state. This has also
been found in the work by Inoue et al
23 and Matsui et al.
24 To
overcome this discrepancy, transforming the DAS28 (CRP) to
more closely conform to the DAS28 (ESR) is an enticing idea.
However, the concern is the generalisability of the transforma-
tion across different patient groups. Inoue et al
23 derived an
adjustment factor based on regressing DAS28 (ESR) on DAS28
(CRP) (ie, DAS28 (ESR)=1.01 DAS28 (CRP)+0.590). Applying
this adjustment factor to the current dataset led to a larger
percentage being classified with a worse response state using
DAS28 (CRP) (2.9% classified as better and 12.9% classified
worse, compared with the unadjusted results of 12.7% and
4.9%, respectively). Other approaches can be considered, for
example, an adjustment factor could be based on regressing
ln(ESR) on ln(CRP+1), which is the essential difference between
the two DAS28 definitions, and using this adjustment in the
DAS28 (ESR) formula. Applying this adjustment, a more
equitable division resulted, with 4.5% in a better and 8.6% in
a worse state; again, the generalisability of the transformation
may be an issue.
The construct validity of the DAS28 (CRP) was evaluated by
examining the trends in radiographic and functional progression
across the EULAR responder states based on the DAS28 (CRP).
For both definitions of the DAS28 there was generally good
agreement between reduced radiographic progression and
EULAR responses, and classification as a good EULAR responder
was predictive of a lower rate of radiographic progression in
patients treated with abatacept. However, some deviations
from this trend were observed. For the DAS28 (ESR) definition,
radiographic scores were generally higher for the moderate
responders than for non-responders in the placebo group. This
was also true for the DAS28 (CRP) definition, in the abatacept
and placebo groups. Changes in HAQ-DI scores showed very
Figure 2 Improvements in physical function across European League
Against Rheumatism (EULAR) states based on 28-joint Disease Activity
Score (DAS28) C-reactive protein (CRP) and DAS28 erythrocyte
sedimentation rate (ESR) for patients in the ATTAIN (Abatacept Trial in
Treatment of Anti-TNF INadequate responders) and AIM (Abatacept in
Inadequate responders to Methotrexate) trials (both treatment groups).
Mean improvement from baseline in Health Assessment Questionnaire
Disability Index (HAQ-DI), for combined abatacept and patients treated
with placebo who were EULAR good, moderate or non-responders based
on DAS28 (CRP) or DAS28 (ESR). A. Mean improvement from baseline
to 6 months for patients in the ATTAIN trial. B. Mean improvement from
baseline to 6 months for patients in the AIM trial. Error bars represent
the standard error of the mean (SEM).
Table 4 Functional progression (Health Assessment Questionnaire Disability Index (HAQ-DI)) across the European League Against Rheumatism
(EULAR) states based on the 28-joint Disease Activity Score (DAS28) C-reactive protein (CRP) and DAS28 erythrocyte sedimentation rate(ESR): mean
change from baseline
Trial EULAR response
Abatacept group Placebo group Combined group
CRP ESR CRP ESR CRP ESR
(n=171) (n=75) (n=246)
ATTAIN (6 months) Good 21.00 (0.10) 20.82 (0.13) 20.56 (0.28) 20.63 (0.38) 20.95 (0.09) 20.80 (0.12)
Moderate 20.49 (0.06) 20.56 (0.06) 20.21 (0.06) 20.28 (0.06) 20.43 (0.05) 20.50 (0.05)
None 20.18 (0.06) 20.21 (0.05) 20.10 (0.06) 20.07 (0.06) 20.14 (0.04) 20.14 (0.04)
(n=351) (n=155) (n=506)
AIM (6 months) Good 20.89 (0.06) 20.97 (0.07) 21.03 (0.16) 21.20 (0.24) 20.91 (0.05) 20.99 (0.06)
Moderate 20.55 (0.04) 20.57 (0.04) 20.66 (0.06) 20.71 (0.07) 20.59 (0.03) 20.61 (0.03)
None 20.11 (0.05) 20.16 (0.06) 20.18 (0.07) 20.20 (0.07) 20.15 (0.05) 20.18 (0.05)
Data are mean (SD).
AIM, Abatacept in Inadequate responders to Methotrexate; ATTAIN, Abatacept Trial in Treatment of Anti-TNF INadequate responders.
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HAQ-DI across the EULAR responder states from none to
moderate to good. These trends held for patients treated with
abatacept and placebo, and demonstrate that improvements in
the DAS28 (CRP) and DAS28 (ESR) are associated with
improvements in physical function.
The level of sensitivity of the DAS28 (CRP) and DAS28 (ESR)
is an important issue to consider, and differences could
potentially contribute to discrepancies observed between the
two measures. However, as the SRMs were identical for the two
measures, and the relative efficiencies were comparable,
suggesting the sensitivity to change of the DAS28 (CRP) and
DAS28 (ESR) are very similar.
The analyses described here were performed only on patients
for whom ESR and CRP measurements were available. The
majority of patients who did not have both measurements had
missing ESR data. This was due to technical issues associated
with the fact that ESR assessments were performed locally on
standard kits, whereas CRP was measured by a central
laboratory, allowing electronic data transfer to the main
database. Although only a subset of patients from each trial
had CRP and ESR measurements, baseline demographics and
clinical characteristics for this subset were comparable with
those that did not have both measurements, suggesting that
they were likely to be representative of the full patient
population.
Two key findings have emerged from the current investiga-
tion. Firstly, the DAS28 (CRP) has been validated with respect
to functional and radiographic progression, and the validation
profile was similar to that based on ESR. Secondly, there was a
tendency for the DAS28 (CRP) to yield a lower score and in
some instances a better EULAR response (12.7% vs 4.9% for the
CRP and ESR, respectively). Often the two definitions were
generally comparable, and formulating a conclusion on the
EULAR response state or remission status based on the DAS28
(CRP) definition provides a reasonable basis for assessing a
patient, provided the user is aware of the tendency of the
DAS28 (CRP) to yield a better response than the DAS28 (ESR).
Currently, the same cut-off points for EULAR response states
originally derived for the DAS28 (ESR) are also applied for the
DAS28 (CRP). To increase the level of agreement between the
two DAS28 formulations, one solution would be to derive a
new set of cut-off points tailored for use with DAS28 (CRP).
The development of a robust approach leading to set of cut-off
points that can be generally applied across populations may
prove difficult, as illustrated when the translation derived by
Inoue et al
23 and Matsui et al
24 is applied to the current dataset.
Exploration of a robust method that will translate DAS28 (CRP)
to DAS28 (ESR) and the derivation of a corresponding set of
cut-off points for the disease activity state for the CRP
formulation are needed before a transformation of the DAS28
(CRP) definition is advocated. An appropriate research agenda
encompassing the assembly of large and diverse datasets, and an
analysis plan involving regression based models will help to
provide further insight into the potential for achieving a better
alignment of the DAS28 (CRP)-defined and the DAS28 (ESR)-
defined EULAR response states.
In conclusion, we have provided a validation of the DAS28
(CRP) assessment and corresponding EULAR response states
against radiographic progression and physical function. While
the DAS28 (CRP) yielded a better EULAR response more often
than the DAS28 (ESR), the validation profile was similar to that
of the DAS28 (ESR), indicating that both definitions of the
DAS28 criteria can be used as benchmarks to assess patient
improvement and treatment effect, and can aid in the
description and interpretation of changes in disease activity in
patients with RA.
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